This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
A natural compound derived from gut-friendly bacteria significantly slows the pr...
Basal cell carcinomas, the most common form of skin cancer, occur in chronically...
Antibiotic resistance is a global public health crisis responsible for more than...
Biomedical engineers at Duke University have developed an AI-based platform that...
Secondary prevention medications for cardiovascular diseases (CVD) are underused...
For the last 10 years, the only effective treatment for hypophosphatasia (HPP) h...
Tuberculosis is a serious global health threat that infected more than 10 millio...
Many people would like to delay or even stop the aging process. Previous clinica...
After combing through 4,000 existing medications, an artificial intelligence too...
Elsewhere, cell therapy developer Turnstone Biologics announced a second round o...
CagriSema, which underperformed expectations in its first Phase 3 test, will be ...
Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to ...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
That includes treating more than 200,000 patients with the irregular heartbeat k...
Glucotrack has cleared the first human clinical study of its long-term continuou...
X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as...
AstraZeneca has ended development of its oral factor D inhibitor vemircopan, tri...
LinusBio aims to help physicians rule out the likelihood of autism developing in...
The “New BD,” as the company describes it, will continue on as a pure-play medte...
Kura Oncology and Kyowa Kirin claim to have scored a phase 2 win for their oral ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside ...
Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joi...
Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease speci...
After sharing plans to shutter last summer, Asarina Pharma has managed to sell o...